FDA Expands Mavacamten for Children with oHCM

The FDA announced Wednesday the approval of mavacamten (Camzyos) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in children, according to a release.¹ With efficacy data exhibiting improvements in functional capacity and patient symptoms, this therapy expansion is the first of its kind across childhood populations.

“This approval represents an important change in the treatment landscape because it gives pediatric cardiologists for the first time a therapy that directly targets the underlying hypercontractility responsible for obstruction in hypertrophic cardiomyopathy,” said Joseph Rossano, MD, cardiology division chief at Children’s Hospital of Philadelphia, according to Contemporary Pediatrics.² “Historically, treatment in this age group has relied largely on medications such as beta-blockers or calcium-channel blockers, with much of that practice extrapolated from adult experience.”

The landmark label expansion is backed by clinical evidence from the phase 3 SCOUT-HCM trial, an international study involving 44 patients aged 12 to 18 years weighing at least 30 kilograms. Over a 28-week period, mavacamten significantly reduced the Valsalva-provoked left ventricular outflow tract pressure gradient compared with placebo. The indicated mechanism directly addresses the primary physical obstruction that restricts blood flow leaving the heart.^1,2

Furthermore, trial participants demonstrated notable enhancements in functional capacity and daily symptom management without any observed drop in left ventricular ejection fraction below 50%.

READ MORE: Pharmacists Are Vital in Complex, Team-Based Treatment of PAD

OHCM is a genetic heart muscle disorder where abnormal wall-thickening causes exercise intolerance, shortness of breath, severe fatigue, and potential cardiac arrhythmias.^1,2

Before this landmark decision, young patients with symptomatic disease depended primarily on non-specific symptom management or invasive procedures like surgical myectomy. However, surgical options carry inherent procedural risks and are generally restricted to specialized centers of excellence, creating geographic travel barriers for families across many states while opening the door for new therapies like this one.^2,3

Clinical Evidence and Managed Care Evaluation

For pharmacists, evaluating mavacamten requires understanding the heterogeneous nature of the condition, where daily symptoms can fluctuate unpredictably for individual patients. Conventional pharmacotherapy relies heavily on beta-blockers and calcium channel blockers, while disopyramide faces persistent long-term supply chain shortages.³

Managed care policies must balance drug access without imposing mandates that require invasive surgery prior to approving novel medical therapies. Pharmacists also analyze patient-reported outcomes to measure meaningful gains in physical function and overall quality of life.

Safety monitoring remains a central priority for pharmacy teams managing pediatric patients on mavacamten. The drug contains a boxed warning for the risk of heart failure and is restricted to a specialized Risk Evaluation and Mitigation Strategy (REMS) program.¹

Pharmacists actively monitor patients for common adverse events such as dizziness and fainting while verifying that cardiac function is routinely assessed. Additionally, pharmacists offer essential counseling regarding proper storage, potential drug interactions, and strict administration schedules to prevent medication errors.^1,4,5

Expanding the Pharmacist’s Role in Pediatric Care

Beyond distribution and safety protocols, community and clinical pharmacists play a crucial role in supporting long-term treatment adherence for oHCM. Research suggests that nearly half of all medications prescribed for chronic diseases are not taken correctly, making routine pharmacist engagement indispensable for young patients.^4,5

Pharmacists assist families by establishing medication synchronization, organizing compliance packaging, and coordinating care with pediatric cardiologists.⁵

Managing chronic heart conditions can also present financial and logistical challenges for families. Pharmacists help navigate prescription affordability through manufacturer discount programs, generic alternatives, and co-pay assistance options. Through comprehensive medication reviews, lifestyle counseling, and ongoing tracking, pharmacists empower families to achieve safer medication routines and better health outcomes.^4,5

“Managing a heart condition can feel overwhelming, but [it doesn’t have to be done] alone. [A] local pharmacist is one of your most valuable partners in heart care,” concluded HealthFirst Pharmacy.⁵ “From explaining medications to monitoring interactions and helping stay on track, pharmacists offer everyday support that helps [patients] live longer, healthier, and with greater peace of mind.”

READ MORE: Cardiology Resource Center

REFERENCES

1. FDA approves first drug to improve functional capacity and symptoms in children with rare inherited heart condition. FDA. News Release. September 30, 2026. Accessed October 1, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-improve-functional-capacity-and-symptoms-children-rare-inherited-heart

2. Ebert M. FDA approves Camzyos for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy. Contemporary Pediatrics. September 30, 2026. Accessed October 1, 2026. https://www.contemporarypediatrics.com/view/fda-approves-camzyos-for-adolescents-with-symptomatic-obstructive-hypertrophic-cardiomyopathy

3. Taddei-Allen P. Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy. J Manag Care Spec Pharm. 2022 Mar;28(3):376-378. doi: 10.18553/jmcp.2022.28.3.376

4. Merschel M. A pharmacist's guide to taking medications safely. American Heart Association. January 28, 2025. Accessed October 1, 2026. https://www.heart.org/en/news/2025/01/28/a-pharmacists-guide-to-taking-medications-safely

5. How pharmacists help patients with heart conditions. HealthFirst Pharmacy. Accessed October 1, 2026. https://www.healthfirsthagerstown.com/blogs/how-pharmacists-help-patients-with-heart-conditions